The antiphospholipid syndrome is characterized by thrombosis and recurrent fetal loss in
patients with antiphospholipid antibodies (APLAs). Most pathogenic APLAs are directed …

Objective. To investigate the prevalence and significance of the autoantibodies against
complement component 1 q subcomponent (C1q) in patients with APS. Methods. In all, 40 …

Antiphospholipid syndrome (APS) is a complex thrombo-inflammatory autoimmune disease
characterized by the presence of antiphospholipid antibodies (aPL). Women with APS are at …

Increased mean platelet volume (MPV) is associated with platelet reactivity and is a
predictor of cardiovascular risk and unprovoked venous thromboembolism. The aim of our …

Posttranslational modifications (PTMs) are defined as covalent modifications occurring in a
specific protein amino acid in a time-and signal-dependent manner. Under physiological …

Objective Heparin‐binding epidermal growth factor–like growth factor (HB‐EGF) plays a role
in blastocyst implantation and is down‐regulated in preeclampsia and in hypertensive …

Circulating antiphospholipid antibodies (aPL) are associated with central nervous system
dysfunction in antiphospholipid syndrome (APS) patients and in a mouse model of APS. We …

Almost 30 years after it was first described as a discrete clinical entity, the antiphospholipid
syndrome (APS) remains a challenge for clinicians in a wide range of specialities. There …

The antiphospholipid syndrome (APS) is characterized by recurrent vascular thrombosis,
thrombocytopenia, and fetal loss occurring in the presence of antiphospholipid antibodies …

Background Antiphospholipid syndrome is associated with endothelial dysfunction, which
leads to thrombosis and early atheroma. Given that hydroxychloroquine has anti-thrombotic …